Emavusertib hydrochloride

Product NameEmavusertib hydrochloride
CAS2376399-42-5
MFC24H25N7O5.ClH
MW527.96
EINECS
MOL File2376399-42-5.mol

Usage And Synthesis

Uses

Emavusertib hydrochloride (CA-4948 tosylate) is the hydrochloride salt form of Emavusertib (HY-135317). Emavusertib hydrochloride is an orally active inhibitor for IRAK4 (IC50=57 nM) and FLT3. Emavusertib hydrochloride inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib hydrochloride exhibits antitumor activity in mouse model[1][2][3].

in vivo

Emavusertib (25-150 mg/kg, Orally, once daily, for 14 consecutive days) induces tumor growth inhibition in mice^[3].

Animal Model:	Mice bearing OCI-LY10 tumors^[3]
Dosage:	25, 50, or 150 mg/kg (once daily), 12.5, 25, or 50 mg/kg (twice daily)
Administration:	Orally, once daily or twice daily, for 14 consecutive days
Result:	Induced tumor growth inhibition. Emavusertib administered as a twice-daily divided dose was equivalent to the corresponding once-daily dose with regards to antitumor activity, i.e., 12.5 mg/kg BID versus 25 mg/kg QD.

IC 50

IRAK4: 57 nM (IC₅₀)

References

[1] Wiese MD, et al. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2020 Apr 17:1-8. DOI:10.1080/13543784.2020.1752660
[2] Guidetti F, et al. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors. J Clin Med. 2023 Jan 4;12(2):399. DOI:10.3390/jcm12020399
[3] Parrondo RD, et al. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies. Front Immunol. 2023 Oct 26;14:1239082. DOI:10.3389/fimmu.2023.1239082

Emavusertib hydrochloride Supplier

Related Product Information

Send Inquriy